Dr Datsons Labs inks supply pact with Yemen's Al-Mugdh Pharma for anti-malarial drugs

Dr Datsons Labs has signed a licensing, distribution and supply deal with Yemen's Al-Mugdh Pharma to sell its anti-malarial drugs in that country. Dr Datsons Labs is revamping its factory in Pune to cater to the overseas market and the company estimates to receive orders to the tune of Rs 80 crore from Yemen.
 
Sameer Talim, CEO, Dr Datsons Labs, said, "The talk between the two companies was going on for last six months and there are certain regulatory aspects that need to be addressed before the commercialisation of the five products to be exported to Al-Mugdh Pharma."
 
Dr Datsons will supply products such as codeine phosphate, artesunate & amodiaquine, mefloquine & artesunate, quinine sulphate, etc.
 
The pharmaceutical market in Gulf Cooperation Council (GCC) countries, especially Yemen, is growing rapidly and is projected to grow into an estimated $10-bn. The GCC and Yemen currently imports about 90% of its medicine requirements.
 
Dr Datsons Labs is looking to widen its product basket to cater to regulated and semi-regulated markets. The company is also venturing into nutraceutical manufacturing through collaboration with Belgium company Eubage.